Nevertheless, studies have shown that the combination of conventional chemotherapy with inhibitors of MEK, B-cell lymphoma-extra large (BCL-XL), and phosphoinositide 3-kinase is a promising method for the prevention and treatment of KRAS-mutant lung cancer [8,9]. This evidence concerns the gene KRAS and lung carcinoma.